STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Syra Health Corp Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Syra Health Corp. reported the results of its Annual Meeting of Stockholders. A total of 15,848,410 shares were represented, including 600,000 shares of Class B common stock with 16.5 votes per share.

All five director nominees were elected. Stockholders ratified M&K CPAs, PLLC as independent auditor for the year ended December 31, 2025 with 14,955,596 For, 369,733 Against, and 523,081 Abstain.

Two charter amendments affecting Class B voting structure were approved: (1) deletion of the provision that automatically converts Class B common stock upon the death of a Class B stockholder; and (2) expansion of permitted transfers so that immediate family members, heirs, successors, and assigns may receive Class B shares without those shares converting.

Positive
  • None.
Negative
  • None.

Insights

Shareholders kept Class B voting intact across death and family transfers.

The meeting confirmed the board slate and auditor, indicating continuity. More notably, stockholders approved two amendments that preserve Class B voting rights by removing automatic conversion upon a holder’s death and allowing transfers to immediate family members, heirs, successors, and assigns without conversion.

These changes can sustain the existing voting control mechanics tied to Class B stock. Outcomes still depend on the distribution of Class B holdings and future transfers, as permitted under the revised charter language.

false 0001922335 0001922335 2025-11-14 2025-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 14, 2025

 

SYRA HEALTH CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41822   85-4027995
(State or other jurisdiction   (Commission   (I. R. S. Employer
of incorporation)   File Number)   Identification No.)

 

1119 Keystone Way N. #201

Carmel, IN 46032

(Address of principal executive offices, including zip code)

 

(463) 345-8950

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, $0.001 par value   SYRA   OTCQB

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On November 14, 2025, Syra Health Corp. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 15,848,410 shares of common stock (including 600,000 shares of Class B common stock with each share of Class B common stock having 16.5 votes per share), constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on September 19, 2025 are as follows:

 

Proposal 1. All of the five (5) nominees for director were elected to serve until the 2026 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the five (5) directors was as follows:

 

Directors  For   Against   Abstain   Broker Non Vote 
Priya Prasad  9,093,067   -   4,508,108   2,247,235 
Dr. Vijayapal R. Reddy  9,091,897   -   4,509,278   2,247,235 
Dr. Ketan Paranjape  9,093,067   -   4,508,108   2,247,235 
Dr. Avutu S. Reddy  9,091,917   -   4,509,258   2,247,235 
Radhika Mereddy  8,897,555   -   4,703,620   2,247,235 

 

Proposal 2. The appointment of M&K CPAs, PLLC, as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2025 was ratified and approved by the stockholders by the votes set forth in the table below:

 

For   Against   Abstain   Broker Non Vote 
14,955,596   369,733   523,081   - 

 

Proposal 3. The amendment to the Company’s Amended and Restated Certificate of Incorporation to delete Article IV, Section 4.2.8(D) in its entirety which allows for the automatic conversion of Class B Common Stock upon death of a Class B stockholder was approved by the stockholders by the votes set forth in the table below:

 

For   Against   Abstain   Broker Non Vote 
8,917,010   4,632,013   52,152   2,247,235 

 

Proposal 4. The amendment to Section 4.2.8 of the Company’s Amended and Restated Certificate of Incorporation to add immediate family members, heirs, successors and assigns as parties to whom the Class B stockholder can transfer shares to without such Class B shares being converted was approved by the stockholders by the votes set forth in the table below:

 

For   Against   Abstain   Broker Non Vote 
8,880,105   4,631,020   90,050   2,247,235 

 

-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SYRA HEALTH CORP.
     
Date: November 14, 2025 By: /s/ Priya Prasad
    Priya Prasad
   

Interim Chief Executive Officer and Chief Financial Officer

 

-3-

FAQ

What did SYRA stockholders approve at the Annual Meeting?

They elected five directors, ratified M&K CPAs, PLLC as auditor, and approved two charter amendments affecting Class B conversion and transfer rules.

How many shares were represented for SYRA at the meeting?

A total of 15,848,410 shares were represented, including 600,000 Class B shares with 16.5 votes per share.

Who was elected to the Syra Health (SYRA) board?

Five nominees were elected: Priya Prasad, Dr. Vijayapal R. Reddy, Dr. Ketan Paranjape, Dr. Avutu S. Reddy, and Radhika Mereddy.

Which auditor did SYRA stockholders ratify?

M&K CPAs, PLLC was ratified for the fiscal year ended December 31, 2025, with 14,955,596 votes For.

What Class B charter changes did SYRA approve?

Stockholders deleted automatic conversion upon a Class B holder’s death and allowed transfers to immediate family, heirs, successors, and assigns without conversion.

What is the voting power of SYRA's Class B shares?

Each Class B common share carries 16.5 votes per share.
Syra Health

OTC:SYRA

SYRA Rankings

SYRA Latest News

SYRA Latest SEC Filings

SYRA Stock Data

4.75M
7.48M
13.48%
1.52%
3.38%
Medical Care Facilities
Services-employment Agencies
Link
United States
CARMEL